{"title": "Homeopathic Medicinal Products Working Group (HMPWG)", "author": null, "url": "https://www.hma.eu/about-hma/working-groups/homeopathic-medicinal-products-working-group.html", "hostname": "hma.eu", "description": null, "sitename": "hma.eu", "date": "2021-01-01", "cleaned_text": "Introduction/Mandate/Rules of Procedure Introduction European group dedicated to homeopathic medicinal products for human and veterinary use Mandate - To create a forum for exchange of regulatory and scientific expertise regarding the assessment of the quality, safety and homeopathic use of homeopathic medicinal products for human and veterinary use; - To provide guidance on the assessment of homeopathic medicinal products on request from Competent Authorities; - To provide guidance for applicants on the registration of homeopathic medicinal products; - To establish one common dossier template for applications for the registration (Article 14 of Directive 2001/83/EC, as amended) of homeopathic medicinal products in the EU, in co-operation with the Notice to Applicants Group; - To provide advice and expertise on request of the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMD(h)) and Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary (CMD(v)) on procedural, regulatory and scientific issues arising from the mutual recognition and decentralised procedures applicable to homeopathic medicinal products; - To facilitate the resolution of procedural, regulatory, and scientific issues arising from variation procedures pertaining to homeopathic medicinal products; - To support the drafting of a list of safe dilution grades for homeopathic medicinal products; - To address regulatory and scientific issues concerning homeopathic medicinal products on request by the European Commission, the CMD(h), the CMD(v), the Heads of Medicines Agencies and the EDQM; - To draft rules of procedure for approval by the Heads of Medicines Agencies; - To prepare guidance documents which will be presented to the Heads of Medicines Agencies for publication on their website; - To ensure reporting for the Heads of Medicines Agencies. Rules of Procedure [HMPWG's Rules of Procedure](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2022_01_HMPWG_RoP.pdf) | pdf Document adopted at HMA meeting in Dublin 30/01/2013, as amended by HMPWG at the 23rd meeting in Utrecht 14-15/04/2016, the 29th meeting in Bucharest 23-24/05/2019, the 34th meeting in Paris 12-13/05/2022 and by written procedure on 15/9/2022. Members and Representatives - The HMPWG is composed of representatives from the National Competent Authorities (NCAs) and a veterinarian representative . Representatives of the European Commission (EC) and European Medicines Agency (EMA) are invited to attend all meetings of the HMPWG. Observers from European Directorate for the Quality of Medicines and Healthcare (EDQM), the EFTA countries and the World Health Organisation (WHO) may also participate. - Meeting cycle: 2 meetings/year, once per EU presidency - Chair: Awaiting election Contact Contact Point: [HMPWG-Secretariat](#)@ hma .eu [Template for submission of request to HMPWG](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/Template_for_submission_of_request_to_HMPWG.docx)| word Adopted by HMPWG on 18 October 2018 [Guidance document on submission of request to the HWPWG](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_07_HMPWG_Guidance_on_submission_of_request_to_HMPWG.pdf)| pdf Adopted by HMPWG on 31 May 2018 Reports Reports from meetings - 27-28 October 2022, Rome (Italy): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2023_04_HMPWG_35_Meeting_Public_Report_Rome.pdf)| pdf Adopted in March 2023 - 12-13 May 2022, Paris (France): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2022_HMPWG_34_meeting_Public_Report.pdf)| pdf Adopted - 10 November 2021, Ljubljana (Slovenia): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/HMPWG_33meeting_10112021_PublicReport.pdf)| pdf Adopted by written procedure in January 2022 - 28 January 2021, Lisbon (Portugal): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2021_01_HMPWG_Virtual_Meeting_Public_Report_Lisbon_32_meeting.pdf)| pdf Adopted by written procedure in April 2021 - 01-02 September 2020, Bonn (Germany) [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2020_10_HMPWG_Meeting_Public_Report_Bonn_31_meeting.pdf)| pdf Adopted by written procedure in October 2020 - 24-25 October 2019, Bucharest (Romania): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2020_01_HMPWG_Public_Report_30th_Meeting_Bucharest.pdf)| pdf Adopted by written procedure in December 2019 - 23-24 May 2019, Bucharest (Romania): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2020_01_HMPWG_Public_Report_29th_Meeting_Bucharest.pdf)| pdf Adopted in October 2019 - 18-19 Oct 2018, Vienna (Austria): [report](/fileadmin/_migrated/HMPWG_Vienna_Public_Report_final.pdf)| pdf Adopted by written procedure in February 2019 - 17-18 May 2018, Berlin (Germany): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_09_HMPWG_public_report_27th_meeting.pdf)| pdf 10-11 November 2016, Bern (Switzerland): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2017_02_HMPWG_Public_Report_Nov_2016.pdf)| pdf Adopted by written procedure in January 2017 - 14-15 April 2016, Utrecht (The Netherlands): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2016_07_HMPWG_Public_Report_April_2016.pdf)| pdf Adopted by written procedure in June 2016 - 11-12 November 2015, Utrecht (The Netherlands): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2016_01_HMPWG_Public_Report_Nov__2015.pdf)| pdf Adopted by written procedure in January 2016 - 28-29 May 2015, Strasbourg (France): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2015_05_HMPWG_Public_Report_21_meeting_Strasbourg.pdf)| pdf - 4-5 December 2014, Rome (Italy): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2014_12_HMPWG_Rome.pdf)| pdf - 5-6 June 2014, Paris (France): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2014_07_HMPWG_Public_Report_19th_meeting.pdf)| pdf [Revision](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2014_12_HMPWG_corrigendum_Public_Report_19th_HMPWG.pdf)to Public Report | pdf - 21-22 November 2013, Bonn (Germany): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2014_01_HMPWG_Public_Report_18th_meeting.pdf)| pdf - 30-31 May 2013, Dublin (Ireland): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2013_07_HMPWG_Public_Report_17th_HMPWG_meeting.pdf)| pdf - 23 October 2012, Gdansk 5-6 June 2012, - 7-8 June 2011, Budapest (Hungary): [report](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2011_06_HMPWGReportBudapestMeeting.pdf)| pdf Other reports [HMPWG Report on the Regulatory Status of Homeopathic Medicinal Products for Human Use in EU/EEA Countries - Update - 2022](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2022_HMPWG_report_on_HMPs.pdf)| pdf Adopted by consensus at the 36th HMPWG meeting (29-30 March 2023) under the Swedish Presidency [HMPWG Report on the Regulatory Status of Homeopathic Medicinal Products for Human Use in EU And EFTA Countries](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2017_04_HMPWG_Report_Regulatory_status_Homeopathic_Medicinal_Products.pdf)| pdf Adopted by written procedure in February 2017 Public Consultation Documents for public consultation / Templates for public consultations [Template for submission of comments on draft document](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2013_11_HMPWG_Template_Sub_Comments.doc)| doc Adopted November 2013 General Guidance/Regulatory and Legal issues/Notice to Applicants General Guidance [List of Terms used in Homeopathic Medicinal Products](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2014_11_HMPWG_LIST_OF_TERMS_Adopted.pdf)| pdf Adopted by HMA 27 November 2014 Regulatory and Legal Issues [Questions and answers document on regulatory and legal issues concerning homeopathic medicinal products in the European framework](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2020_09_HMPWG_QA_document_on_regulatory_and_legal_issues_re_HMPs.pdf)| pdf Final confirmation from the European Commission 29 July 2020 The document is currently under revision as far as veterinary homeopathic medicinal products are concerned. The updated version will include specific references to the veterinary Regulation (EU) 2019/06 applicable from 28th January 2022. Notice to Applicants [Notice to Applicants Volume 2B Module 1 - Homeopathic application form](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2017_11_HMPWG_vol2b_applicationform_homeo_rev1_201612.doc)| doc Revised December 2016 [Eudralex website](https://ec.europa.eu/health/documents/eudralex/vol-2_en) Subworking Groups Quality [Mandate of sub-Working Group on Quality](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2016_02_HMPWG_Mandate_sub_WG_Quality.pdf)| pdf Adopted by HMA MG on 2 February 2016 [Work Programme of sub-Working Group on Quality](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2016_02_HMPWG_work_programme_sWG_Quality.pdf)| pdf Adopted by HMA MG on 2 February 2016 Homeopathic Use [Mandate of the Homeopathic Use sub-group](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2015_11_HMPWG_subgroup_mandate.pdf)| pdf Adopted November 2015 First Safe Dilutions [FSD Sub-working group Mandate](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2013_05_HMPWG_FSD_mandate.pdf)| pdf Adopted May 2013 [FSD Sub-working group General Work Programme](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2013_05_HMPWG_FSD_WP.pdf)| pdf Adopted May 2013 Guidance documents on Quality The documents in this section are also valid for veterinary homeopathic medicinal products as far as applicable. Guidance documents [Guidance on module 3](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2007_11_HMPWG_dossier_guidance_mod3.pdf)| pdf November 2007 [Guidance on module 3.2.S for Nosodes](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_12_HMPWG_Guidance_on_module_3.2.S_for_Nosodes.pdf)| pdf Adopted by HMPWG October 2018 [Points to Consider on selection of Microbial limits for non-sterile homeopathic raw materials, stocks, preparations and products](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2017_10_HMPWG_PtC_microbial_limits.pdf)| pdf Adopted by HWPWG June 2017 [Points to consider on Stability Testing of HMPs](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2009_07_Points_on_Stability_testing.pdf)| pdf Approved by HMPWG July 2009 Questions and answers [Questions and Answers document on the quality of homeopathic medicinal products (Q 1-2)_raw materials](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.1_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_1-2_.pdf) Adopted by HMPWG on 23-24 May 2019 [Questions and Answers document on the quality of homeopathic medicinal products (Q 3)_raw materials](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2019_12_HMPWG_Q_A_on_Quality_Q_3.pdf) Adopted by HMPWG on 15 November 2019 [Questions and Answers document on the quality of homeopathic medicinal products (Q 4-5)_stability_manufacturing](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.2_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_4-5_.pdf) Adopted by HMPWG on 23-24 May 2019 [Questions and Answers document on the quality of homeopathic medicinal products (Q 6-7)_process validation_specification and testing](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.3_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_6-7_.pdf) Adopted by HMPWG on 23-24 May 2019 [Questions and Answers document on the quality of homeopathic medicinal products (Q 8)_manufacturing](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.4_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_8_.pdf) Adopted by HMPWG on 23-24 May 2019 [Questions and Answers document on the quality of homeopathic medicinal products (Q 9)_GMP compliance](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2023_01_HMPWG_Q_A_on_Quality_Q9_GMP_compliance.pdf) Adopted by HMPWG on 27-28 October 2022 [Questions and Answers document on the quality of homeopathic medicinal products (Q 10)_microbiological quality](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.5_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_10_.pdf) Adopted by HMPWG on 23-24 May 2019 [Questions and Answers document on the quality of homeopathic medicinal products (Q 11-12)_impurities](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.6_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_11-12_.pdf) Adopted by HMPWG on 23-24 May 2019 [Questions and Answers document on the quality of homeopathic medicinal products (Q 13)_stability](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2023_01_HMPWG_Q_A_on_Quality_Q13_stability.pdf) Adopted by HMPWG on 27-28 October 2022 Overview of comments [Overview of comments on Guidance for Nosodes](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_12_HMPWG_OoCs_on_Guidance_for_nosodes.pdf)| pdf Adopted by HMPWG October 2018 [Overview of comments received on draft document \"Points to Consider on Selection of Microbial Limits for Non-sterile Homeopathic Raw Materials, Stocks, Preparations and Products\"](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2017_10_HMPWG_Overview_of_comments.pdf)| pdf Adopted by HWPWG June 2017 [Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 1-2)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.1_Overview_of_Comments_on_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_1-2_.pdf) Adopted by HMPWG on 23-24 May 2019 [Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 3)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2019_12_HMPWG_Overview_of_comments_Q_A_on_Quality_Q_3.pdf) Adopted by HMPWG on 15 November 2019 [Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 4-5)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.2_Overview_of_Comments_on_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_4-5_.pdf) Adopted by HMPWG on 23-24 May 2019 [Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 6-7)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.3_Overview_of_Comments_on_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_6-7_.pdf) Adopted by HMPWG on 23-24 May 2019 [Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 8)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.4_Overview_of_Comments_on_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_8_.pdf) Adopted by HMPWG on 23-24 May 2019 [Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 9)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2023_01_HMPWG_Overview_of_comments_Q_A_on_Quality_Q9.pdf) Adopted by HMPWG on 27-28 October 2022 [Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 10)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.5_Overview_of_Comments_on_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_10_.pdf) Adopted by HMPWG on 23-24 May 2019 [Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 11-12)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/7.2.6_Overview_of_Comments_on_Questions_and_Answers_document_on_the_quality_of_homeopathic_medicinal_products__Q_11-12_.pdf) Adopted by HMPWG on 23-24 May 2019 [Overview of Comments on Questions and Answers document on the quality of homeopathic medicinal products (Q 13)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2023_01_HMPWG_Overview_of_comments_Q_A_on_Quality_Q13.pdf) Adopted by HMPWG on 27-28 October 2022 Guidance documents on Homeopathic Use Guidance documents [Points to consider on the justification of homeopathic use of stock (June 2012)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2012_06_HMPWGPointsConsiderJustificationUse.pdf)| pdf [Preamble to the consolidated list of justified homeopathic stocks](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_07_HMPWG_preamble_consolidated_list.pdf)| pdf Adopted May 2018 [Consolidated list of stocks for which homeopathic use is justified](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_07_HMPWG_consolidated_list_de_1-6.pdf)| pdf Adopted May 2018 This is a final comprehensive document of the previous adopted lists 1-6, sorted alphabetically by the GHP/German traditional name of the stock. [Consolidated list of stocks for which homeopathic use is justified](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_07_HMPWG_consolidated_list_fr_1-6.pdf)| pdf Adopted May 2018 This is a final comprehensive document of the previous adopted lists 1-6, sorted alphabetically by the FP/French traditional name of the stock. Overview of comments [Overview of comments received on the draft version of the preamble](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_07_HMPWG_Comments_stakeholders__preambles_jhu_outcomes.pdf)| pdf Adopted May 2018 [Overview of comments received on the draft version of the Sixth list](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_07_HMPWG_Comments_stakeholders__6thlist_jhu_outcomes.pdf)| pdf Adopted May 2018 [Overview of comments received on the draft version of the Fifth list](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2017_06_HMPWG_Overview__comments_5th_list.pdf)| pdf Adopted June 2017 [Overview of comments received on draft version of the Fourth list](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2016_11_HMPWG_Comments_Fourth_list_entries.pdf)| pdf Adopted November 2016 [Overview of the comments received on Preamble to the consolidated list of justified stocks](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2016_06_HMPWG_Overview_comments_Preamble_list.pdf)| pdf Adopted June 2016 [Overview of comments received on draft version of the Third list](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2015_08_HMPWG_Overview_comments_third_list_entries.pdf)| pdf Adopted May 2015 [Overview of comments received on draft version of the Second list](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2015_03_HMPWG_Overview_comments_second_list_entries.pdf)| pdf Adopted December 2014 [Answer of the HMPWG to the stakeholders after the public consultation on the First list](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2013_09_JofH_Use_Answer_to_stakeholders_public_consultation_firstlist.pdf)| pdf Guidance documents on Safety Guidance Documents [Guidance on non-clinical documentation in applications for registration of homeopathic medicinal products for human use](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/HMPWG_Guidance_on_non-clinical_documentation_in_applications_for_registration.pdf)| pdf Adopted November 2021 [Points to consider on non-clinical safety of homeopathic medicinal products of botanical, mineral and chemical origin](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2007_07_biological_safety_bmco.pdf)| pdf July 2007 (Status: superseded by Guidance on non-clinical documentation) [Points to Consider on Safety of Homeopathic Medicinal Products from Biological Origin](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2016_05_HMPWG_PtC_Biological.pdf)| pdf Adopted April 2016 First safe dilutions [Introduction of the List of First Safe Dilutions](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2010_05_HMPWG_First_Safe_Dilutions.pdf)| pdf Adopted May 2010 [Structure of the List of First Safe Dilutions](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2010_05_HMPWG_Stucture_of_List_of_FSD.pdf)| pdf Adopted May 2010 [Preamble to the First List of First Safe Dilutions (FSD)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2016_11_Preamble_First_List_of_FSD.pdf)| pdf Adopted November 2016 [First safe dilutions where homeopathic use is justified (Consolidated list of FSD, Lists 1-5)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2020_09_HMPWG_First_Safe_Dilutions_Consolidated_list_lists_1-5.pdf)| pdf Published September 2020 [Consolidated List FSD 1-5](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2020_09_HMPWG_Consolidated-List-FSD-1-5.pdf)| pdf This is a final comprehensive document of the previous adopted list 1-5 [Fifth List of First Safe Dilutions](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2019_12_HMPWG_5th_List_FSD.pdf)| pdf Adopted November 2019 Questions and answers [Questions and Answers on First Safe Dilutions](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2015_10_HMPWG_Q_A.pdf)| pdf Adopted October 2015 Overview of Comments/Further Information [Overview of comments received on draft document \"Guidance on non-clinical documentation in applications for registration of homeopathic medicinal products for human use\"](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/HMPWG_Overview_comments_Guidance-non-clinical-safety_Nov_2021.pdf)| pdf Adopted November 2021 [Overview of comments on the draft document \"Fifth List of First Safe Dilutions\"](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2019_12_HMPWG_Overview_Comments_5th-List_FSD.pdf)| pdf Adopted November 2019 [Overview of comments on the draft document \"Fourth List of First Safe Diluitions\"](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2018_12_HMPWG_Overview_comments-4th-List-FSD-final_20181217.pdf)| pdf Adopted November 2018 [Overview of comments received on draft document \"Third List of First Safe Dilutions (FSD)](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/3_Overview_comments-3rd-List_FSD_final_20180130.pdf)| pdf Adopted December 2017 [Overview of comments received on draft document \"Second List of First Safe Dilutions (FSD)\"](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2017_06_HMPWG_Overview_2nd_List_FSD.pdf)| pdf Adopted June 2017 [Overview of comments received on draft documents \"Preamble to the First List of First Safe Dilutions (FSD)\" and \"First List of First Safe Dilutions\"](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2016_11_Overview_comments_Preamble_First_List_FSD.pdf)| pdf Adopted November 2016 [Overview of comments received on Question and Answer document: Issue 1-5](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2015_05_HMPWG_Overview_comments_HMA_Website_QA_1to5.pdf)| pdf Adopted May 2015 [Overview of comments received on Question and Answer document: Issue 6](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2015_06_HMPWG_Overview_comments_HMA_Website_QA_6.pdf)| pdf Adopted June 2015 [Compilation of comments received from public consultation (2012) on FSD assessments](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2014_07_HMPWG_Public_Consulation_2012_Comments_AR.pdf)| pdf Published August 2014 Templates for HMPWG Overview of comments [Template for overview of comments received on draft document](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2013_11_HMPWG_Template_Overview_comments.doc)| doc Adopted November 2013 First Safe Dilutions AR [First Safe Dilutions AR Template](/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/HMPWG/2010_05_FSD_assessment_report_list.pdf)| pdf Adopted May 2010 "}